ADULTS & ADOLESCENTS AGED 12+ YEARS

Reductions in DSQ total score were first observed at Week 4 with treatment with DUPIXENT 300 mg QW (post-hoc analysis; results are descriptive).³

• Part A: 28% reduction (-9 points) from baseline with DUPIXENT (n=42) vs 11% reduction (-4 points) with placebo (n=39)
• Part B: 31% reduction (-12 points) from baseline with DUPIXENT (n=80) vs 16% reduction (-6 points) with placebo (n=79)

DUPIXENT significantly reduced DSQ total scores compared to placebo at Week 24 (coprimary endpoint).³

• Part A: 69% reduction (-21.9 points) from baseline with DUPIXENT (n=42) vs 32% reduction (-9.6 points) with placebo (n=39) (P<0.001)
• Part B: 64% reduction (-23.8 points) from baseline with DUPIXENT (n=80) vs 41% reduction (-13.9 points) with placebo (n=79) (P<0.0001)

DSQ total score reductions were observed for up to 52 weeks with continued weekly DUPIXENT treatment (secondary endpoint).³

• Part A-C: 76% reduction (-23.4 points) from baseline after 52 weeks of treatment with DUPIXENT (n=29) and 66% reduction (-21.7 points) from baseline after switching to DUPIXENT from placebo at Week 24 (n=23)
• Part B-C: 81% reduction (-30.3 points) from baseline after 52 weeks of treatment with DUPIXENT (n=54) and 78% reduction (-27.3 points) from baseline after switching to DUPIXENT from placebo at Week 24 (n=24)

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.³

Total biweekly DSQ scores range from 0 to 84; higher scores indicate greater frequency and severity of dysphagia.¹

VIEW THE CLINICAL RESULTS IN ADULTS & ADOLESCENTS (12+ YEARS)